Further re: Directors' Shareholdings

RNS Number : 5273L

e-Therapeutics plc

03 October 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Further re: Directors' Shareholdings

3 October 2016, Oxford and Newcastle, UK: Further to e-Therapeutics' announcement on 21 September 2016, the Company announces the following additional detail on the increase to Sean Nicolson's shareholding in the Company; this information is made in accordance with the requirements of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Sean Nicolson
2	Reason for the notification
a)	Position/status	Director
b)	Initial notification /Amendment	Amendment
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-Therapeutics plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code		Ordinary shares of 0.1 pence each GB00B2823H99
b)	Nature of the transaction		Award of shares
c)	Currency		GBP
d)	Price(s) and volume(s)		Price(s)	Volume(s)
			14.55 pence	2,166
e)	Aggregated information - Aggregated volume - Price - Aggregated total		2,166 14.55 pence per share £315.15
f)	Date of the transaction		21 September 2016
g)	Place of the transaction		London Stock Exchange (AIM)

Contacts:

e-Therapeutics plc Iain Ross, Chairman Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne-Sewell / Jayne Crook / Emma Barlow	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery. 

e-Therapeutics has a variety of preclinical stage assets, including ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.  

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.

 

END

 

 

DSHLLFIVIFLVIIR